论文部分内容阅读
台湾“经济部”生物技术与制药工业发展推动小组于2月6日正式挂牌成立,主任由廖怡兰博士担任。未来,此一结合产官学界人士的“工业局”外围组织将筛选具市场潜力的产品,引进外资,原则上将以原料药为发展重点,以欧美地区为主要的合作目标,市场将锁定大陆。 该小组的最主要工作是联系、协调及规划发展项目,并与“卫生署”探讨相关法令的修正工作,整合上、中、下游研发与营运体系,在“工业局”规划、辅导
The promotion group for the development of the biotechnology and pharmaceutical industry of the “Ministry of Economic Affairs” of Taiwan was formally established on February 6th. The director was Dr. Liaolan Yi. In the future, the “Industrial Bureau” peripheral organizations that combine industry officials will select products with market potential, and introduce foreign capital. In principle, APIs will be the focus of development, and Europe and the United States will be the main targets of cooperation. The market will target the mainland. . The team’s main task is to contact, coordinate and plan development projects. It also discusses the revision of related laws with the “Department of Health” and integrates the R&D and operating systems of the upper, middle, and lower reaches. It is planned and coached in the “Industrial Bureau”.